{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"1076","value":"294"},{"groupId":"OG001","lowerLimit":"27","upperLimit":"928","value":"280"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"description":"Determine the difference of CD4+ lymphocyte recovery between the two arms on day 360","dispersionType":"Full Range","groups":[{"description":"Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on day 0. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic hematopoietic stem cell transplant\n\nCliniMACS","id":"OG000","title":"Bulk SCT"},{"description":"Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on days 0, 2, 4, and 6. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic hematopoietic stem cell transplant\n\nCliniMACS","id":"OG001","title":"Fractionated SCT"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"360 days","title":"Hematopoietic Function on Day 360","type":"SECONDARY","unitOfMeasure":"cells/mm^3"}